Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-10-03
2006-10-03
Morris, Patricia L. (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S317500
Reexamination Certificate
active
07115620
ABSTRACT:
Compounds of Formula I are provided:wherein:R is lower alkyl or branched lower alkyl; andAr is phenyl, phenyl substituted with one or more of halogen, lower alkyl, lower alkoxy, lower alkylthio, lower alkylamino, cyano, or perfluoroalkoxy, or a heteroaromatic moiety; and pharmaceutically acceptable salts thereof.
REFERENCES:
patent: 3461133 (1969-08-01), Stoffel
patent: 4084001 (1978-04-01), Durant et al.
patent: 4152453 (1979-05-01), Durant et al.
patent: 5312919 (1994-05-01), Gulliya et al.
patent: 2003/0119889 (2003-06-01), Elokdah et al.
patent: 0154 819 (1982-04-01), None
patent: 219 483 (1985-03-01), None
patent: 3540919 (1987-05-01), None
patent: 0 718 290 (2002-04-01), None
Zankowska-Jasinska et al, “1,3-Disubstituted 2-thioxo, etc” CA 114: 75036 (1991).
Beckert et al I, “Reaction of oxclic amidines with, etc” CA 113: 97511 (1990).
McDonough, Stefan et al., Drug Development Research, 33, 190-202 (1994).
Lawson, Kim, Pharmacol. Ther., 70(1), 39-63 (1996).
Aguilar-Bryan, Lydia et al., Physiological Reviews, 78(1), 227-245 (1998).
Garcia, Maria L. et al., Advances in Pharmacology, 39, 425-471 (1997).
Atwal, Karnail S., Medicinal Research Reviews, 12(6), 569-591 (1992).
Malmgren, A. et al., The Journal of Urology, 142, 1134-1138 (1989).
Malmgren, A. et al., The Journal of Urology, 143, 828-834 (1990).
Bonev, Adrian et al., Am. J. Physiol., 264, C1190-C1200 (1993).
Fujii, K. et al., Br. J. Pharmacol., 99, 779-785 (1990).
Gopalakrishnan, M., et al., Drug Development Research, 28, 95-127 (1993).
Grant, Thomas L. et al., The Journal of Pharmacology & Experimental Therapeutics, 259, 1158-1164 91991).
Evans, John M. et al., Progress in Medicinal Chemistry, 31, 411-446 (1994).
Badimon et al, “High Density Lipoprotein Plasma Fractions Inhibit Aortic Fatty Streaks in Cholesterol-Fed Rabbits”,Laboratory Investigation, 60(3):455-461 (1989).
Barr et al., “Protein-lipid Relationships in Human Plasma”,American Journal of Medicine, 11:480-493 (1951).
Beckert et al., “Imidazolidinderivate aus Oxalamidinen”,Journal of f. prakt. Chemie. Band, 324(2):227-236 (1982).
Beckert, “Zur Umsetzung von Oxalamidinen mit Heterocumulenen der Kohlensäurereihe zu Imidazolidin-Derivaten”,Journal of f. prakt. Chemie. Band, 332(1):65-82 (1990).
Glass et al., “Tissue Sites of Degradation of Apoprotein A-I in the Rat”,The Journal of Biological Chemistry, 258(11):7161-7167 (1983).
Glomset, “The Plasma Lecithin: Cholesterol Acyltransferase Reaction”,Journal of Lipid Research, 9:155-167 (1968).
Gofman et al., “Ischemic Heart Disease, Atherosclerosis, and Longevity”,Circulation, 34:679-697 (1966).
Gordon et al., “High-Density Lipoprotein Cholesterol and Cardiovascular Disease”,Circulation, 79:8-15 (1989).
Grow et al., “Interchange of Apoprotein Components between the Human Plasma High Density Lipoprotein Subclasses HDL2and HDL3in Vitro”, The Journal of Biological Chemistry, 253(22):8034-8041 (1978).
Kieft et al., “Rapid on-line determination of cholesterol distribution among plasma lipoproteins after high-performance gel filtration chromatography”,Journal of Lipid Research, 32:859-866 (1991).
Lagocki et al., “In VitroModulation of the Apolipoprotein Composition of High Density Lipoprotein”,The Journal of Biological Chemistry, 255(8):3701-3706 (1980).
Mackinnon et al., “Metabolism of High Density Lipoproteins by the Perfused Rabbit Liver”,The Journal of Biological Chemistry, 261(6):2548-2552 (1986).
Miller et al., “Plasma-High-Density-Lipoprotein Concentration and Development of ISCH/EMIC Heart-Disease”,The Lancet, 1:16-19 (1975).
Miller et al., “Relation of Angiographically Defined Coronary Artery Disease to Plasma Lipoprotein Subfractions and Apolipoproteins”,British Medical Journal, 282:1741-1744 (1981).
Picardo et al., “Partially Reassembled High Density Lipoproteins”,Arteriosclerosis, 6(4):434-441 (1986).
Schaefer et al., “Transfer of human lymph chylomicron constituents to other lipoprotein density fractions during in vitro lipolysis”,Journal of Lipid Research, 23:1259-1273 (1982).
Stampfer et al, “A Prospective Study of Cholesterol, Apolipoproteins, and the Risk of Myocardial Infarction”,The New England Journal of Medicine, 325(6):373-381 (1991).
Zankowska-Jasinska et al., “1,3-Disubstituted 2-Thioxo-4,5-Imidazolidinediones and 2,4,5-Imidazolidinetriones and Their Anticonvulsant Activity”,Pol. J. Pharmacol. Pharm., 42:59-68 (1990).
Butera John A
Elokdah Hassan M
Graceffa Russell F
Lennox Joseph R
Primeau John L
Fish & Richardson P.C.
Morris Patricia L.
Wyeth
LandOfFree
1,3-disubstituted-2-thioxo-imidazolidine-4,5-diones as... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 1,3-disubstituted-2-thioxo-imidazolidine-4,5-diones as..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 1,3-disubstituted-2-thioxo-imidazolidine-4,5-diones as... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3654416